Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE)

International Journal of MS Care

Volumn 18, Issue 1, 2016, Pages 9-18

  Fox, Edward J ^a   Vasquez, Alberto ^b   Grainger, William ^c   Ma, Tina S ^d   Von Hehn, Christian ^e   Walsh, John ^e   Li, Jie ^e   Zambrano, Javier ^e  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Neuroscience Associates   (United States)

^c Clinical Research Advantage   (United States)

^d PharmStats Ltd   (United States)

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84954360229     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2014-101     Document Type: Article

References (14)

1. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107.
2. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [published correction appears in N Engl J Med. 2012;1367:1673]. N Engl J Med. 2012;367:1087-1097.
3. Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236-243.
4. Phillips JT, Erwin A, Agrella S, Kremenchutzky M, Kramer J, Fox R. A Delphi panel to address management of gastrointestinal side effects observed with use of delayed-release dimethyl fumarate. Paper presented at: Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the 8th Cooperative Meeting with the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS); May 28-31, 2014; Dallas, TX.
5. Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3:513-519.
6. Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 2007;23:1549-1560.
7. O'Gorman J, Russell HK, Li J, Phillips G, Kurukulasuriya NC, Viglietta V. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37:1402-1419.e5.
8. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care. 2008;14:530-539.
9. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006;144:257-261.
10. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21:1159-1164.
11. Sheftell FD, Feleppa M, Tepper SJ, Rapoport AM, Ciannella L, Bigal ME. Assessment of adverse events associated with triptans: methods of assessment influence the results. Headache. 2004;44:978-982.
12. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage. 1999;18:427-437.
13. Tornatore C, Amjad F. Attenuation of dimethyl fumarate-related gastrointestinal symptoms with montelukast. Poster presented at:68th Annual Meeting of the American Academy of Neurology; April 26-May 3, 2014; Philadelphia, PA.
14. Levinthal DJ, Rahman A, Nusrat S, O'Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:319201.